Efficacy of Magnesium Sulfate as an Adjuvant in Erector Spinae Plane Block as an Anesthetic Post Operative After Modified Radical Mastectomy

Efficacy of Magnesium Sulfate as an Adjuvant to Local Anesthetic in Erector Spinae Plane Block for Post-operative Analgesia After Modified Radical Mastectomy

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05976464

Enrollment

Registered

2023-08-04

Start date

2023-07-21

Completion date

2025-08-25

Last updated

2026-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ESPB, Mg Sulfate,Post Mastectomy

Brief summary

efficacy of magnesium sulfate as an adjuvant in erector spinae plane block as an anesthetic post-operative after modified radical mastectomy

Detailed description

magnesium sulphate as an adjuvant to local anesthetic in erector spinae plane block compared to local anesthetic only in erector spinae plane block

Interventions

DRUGMagnesium sulfate in erector spinae plane block

Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle. General anesthesia will be induced with l/kg fentanyl, 2mg/kg propofol, 0.5 mg/kg atracurium and inhalational anesthesia (sevoflurane) No other narcotic, analgesic or sedative will be administrated during the operative period. BP(SystolicBP, DiastolicBP) and HR will be observed and recorded every 30 min till the end of surgery.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* 1\. ASA I-II. 2. Female patients aged 18-65 years. 3. Scheduled for a modified radical mastectomy with axillary dissection for breast cancer.

Exclusion criteria

1. ASA \< II. 2. more than 65 years old 3. Patients with known allergies to the study drugs 4. Skin infection at the site of needle puncture. 5. Coagulopathy 5\. Drug or as that would interfere with perception and assessment of pain. 6. Uncooperative patients.

Design outcomes

Primary

Measure	Time frame
- The primary outcome measure in this study will be the total dose of morphine consumption during the 24 hour Postoperatively.	Up to 24 hour

Countries

Egypt

Contacts

STUDY_CHAIRmohamed a.m bakr, professor

professor of anesthesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026